Cardiac surgery has undergone remarkable advancements, yet the method of closing the sternum—the breastbone—has remained relatively unchanged for decades. The  Sternal Closure Systems Market  is now experiencing a significant transformation as clinical evidence mounts for advanced fixation technologies. Valued at approximately USD 2.82 billion in 2025 and projected to reach USD 4.57 billion by 2035, this market is growing at a steady CAGR of 4.90%, driven by an aging population, rising cardiac surgery volumes, and a shift toward value-based reimbursement models.

Understanding Sternal Closure Systems

Sternal closure systems are medical devices used to rejoin the two halves of the sternum following a median sternotomy—the most common surgical approach for open-heart procedures like coronary artery bypass grafting and valve replacement. Traditional closure has relied on stainless steel wires, which have been the standard for nearly four decades.

However, modern systems include rigid plate-and-screw fixation, cables, and emerging bioresorbable materials designed to provide more stable closure, particularly for high-risk patients. Multi-center registry data released in 2024 show rigid plate-and-screw fixation techniques lower rates of sternal dehiscence by 40–60% in high-risk cohorts, superseding legacy wire-based structures.

Key Market Drivers

Value-Based Reimbursement Expansion

The Centers for Medicare & Medicaid Services continues to use the Bundled Payments for Care Improvement Advanced model to incentivize cost-efficient cardiovascular care. Coronary artery bypass grafting remains a core clinical episode within this framework, shifting financial responsibility to hospitals for complications occurring within the 90-day post-operative period.

While deep sternal wound infection incidence rates in literature vary from 0.5% to 7.3%, the clinical and financial burden is significant, with some estimates citing average treatment costs for severe complications reaching up to USD 60,000. This economic structure creates a strong incentive for healthcare providers to adopt advanced closure technologies that demonstrate a reduction in sternal dehiscence and infection rates.

Aging Population and Complex Surgical Caseload

Global demographic shifts are creating a substantial increase in the volume of high-risk surgical candidates. By 2050, the proportion of the world’s population aged 80 years or older is projected to rise to approximately 4.1%, a significant increase from 0.6% in 1950.

Elderly patients, particularly octogenarians, frequently present with co-morbidities such as osteoporotic bone tissue, which challenges the efficacy of traditional wire cerclage. Recent clinical trends suggest an increasing preference for rigid plate fixation in this demographic to mitigate the higher risk of sternal non-union.

Obesity and Diabetes Prevalence

The global rise in obesity and diabetes has increased the proportion of cardiac surgery patients at elevated risk for sternal complications. These conditions impair wound healing and bone quality, making rigid fixation systems particularly valuable.

Clinical evidence demonstrates that patients with a BMI above 35 or diabetes benefit significantly from plate-and-screw systems. The economic argument has shifted: while a wire set costs USD 35–80, the downstream expense of a sternal wound infection makes the USD 1,800–3,200 plate-and-screw system a net savings proposition under bundled-payment models.

Technological Advancements

Rigid Fixation Systems

Plates and screws represent the fastest-moving product category in the sternal closure systems market, with a projected CAGR of 8.5% through 2035. Randomized controlled trial data published in 2024 demonstrated a 47% reduction in sternal complications among high-risk patients receiving rigid fixation versus wire cerclage.

Adoption is highest in academic medical centers and large community hospitals that have integrated outcomes-tracking into procurement decisions. The technology provides superior stability, reducing the risk of dehiscence and infection in vulnerable patient populations.

Bioresorbable Closure Platforms

Multiple companies have entered Phase III trials for poly-L-lactic acid and magnesium-alloy sternal plates designed to resorb within 18–24 months. These platforms eliminate the need for hardware removal in patients who develop chronic pain or require re-entry for subsequent cardiac interventions.

If approved by the FDA by 2028–2029, these platforms could unlock a premium pricing tier within the sternal closure systems market and address the estimated 8–12% of patients who currently undergo secondary hardware removal.

Titanium Material Advantages

Titanium alloys, though more expensive, offer superior MRI compatibility and reduced artifact interference for postoperative imaging—a clinically meaningful advantage as cardiac MRI becomes standard follow-up protocol. The sternal closure systems market will see titanium's share accelerate as 3D-printing workflows lower production costs.

Titanium also demonstrates excellent biocompatibility and lower infection risk compared to stainless steel, making it increasingly preferred for high-risk patients.

Regional Market Dynamics

North American Leadership

North America holds the largest share of the sternal closure systems market revenue, at almost 38.5%, owing to the presence of a dense cardiac surgery infrastructure and payer incentives. The United States dominates the region, performing approximately 380,000 open-heart operations annually.

CMS payment reforms have created the single most powerful conversion catalyst for rigid fixation. STS quality benchmarking further incentivizes hospitals to adopt technologies that improve publicly reported outcomes.

Asia-Pacific Growth Acceleration

Asia-Pacific is the fastest growing region, with a CAGR of 10.4% through 2035, driven by new cardiac facilities in India, China and Southeast Asia. China's cardiac surgery volume surpassed 280,000 procedures in 2024, and government mandates requiring Level 3A hospitals to stock at least two closure-device categories have broadened the addressable market.

India's trajectory is steeper: cardiac surgery capacity has doubled since 2019, and the Ayushman Bharat scheme now covers sternotomy procedures for 500 million beneficiaries, creating payer-funded demand in previously underserved states.

European Market Maturity

Europe has the second-highest share at approximately 29%, driven by national cardiovascular programs in Germany, the UK and France. Germany anchors European demand through its network of 79 certified cardiac surgery centers that collectively perform over 80,000 sternotomies per year.

The UK's NHS Long Term Plan earmarked GBP 2.3 billion for cardiovascular services through 2029, including equipment upgrades that encompass closure device modernization. EU MDR implementation has consolidated the competitive field by raising documentation requirements.

Competitive Landscape

The sternal closure systems market is moderately concentrated, with the top 5 companies accounting for an estimated 52-58% share of worldwide revenue. Zimmer Biomet leads with approximately 14-18% share, offering the SternaLock rigid fixation and SternalBand systems. B. Braun Melsungen follows with 8-11% share, focusing on wire systems and titanium closure cables.

DePuy Synthes holds 7-10% share through sternal cable and plate systems, while KLS Martin Group commands 6-9% with titanium plate-and-screw systems. A&E Medical Corporation rounds out the top players with 5-8% share, specializing in the cable closure niche.

Future Outlook

The  Sternal Closure Systems Market  is poised for continued transformation through smart implant integration, personalized 3D-printed hardware, and robotic-assisted closure. The next generation of sternal fixation devices is trending toward sensor-enabled capabilities to support early detection of sternal dehiscence.

Advances in medical-grade titanium 3D printing now allow patient-specific sternal plates to be manufactured within 48 hours of a preoperative CT scan. Academic medical centers are piloting custom-plate workflows that improve anatomical fit and reduce operative time by 12–18 minutes on average.

Robotic surgical platforms are extending beyond intracardiac procedures to include chest closure, integrating force-feedback arms that standardize plate placement and screw torque. The market stands to benefit as robotic standardization lowers the training barrier that currently slows rigid fixation adoption.